Huons, a Korean pharmaceutical manufacturer, said Tuesday that it would transition to a single-CEO system under Song Soo-young following the resignation of Co-CEO Yoon Sang-bae.
Song has a background in management consulting. He previously served as CEO of Deloitte Korea (Deloitte Anjin) and Deloitte Japan (Deloitte Tohmatsu Group), global professional services firms specializing in consulting, audit, and financial advisory, and as senior vice president of PwC Japan.
At Huons, he was appointed as CEO of Huons Global in February 2022, recognized for his experience in management innovation and reform in global companies. In August 2023, he also became president of Huons Japan, leading the company’s expansion into the Japanese market.
Yoon, appointed as CEO in March 2022, previously held leadership positions at Boryung, Dong-A Pharmaceutical, and GSK Korea. His term was originally set to run until March 25, 2025.
Related articles
- Huons Meditech surpasses 20,000 units sold in Dermashine product line
- Huons’ Chinese BTX partner postpones launch of Hutox by 1 year
- Huons Biopharma partners with KIST to develop dry macular degeneration eye drops
- Huons Biopharma partners with VERNI Aesthetics to advance fat-decomposition injection MRC101
- Huons reports 6.3% revenue growth in Q3, focuses on diabetes devices, biopharma expansion
- Huons Meditech expands its global presence at Arab Health 2025
- Huons unveils redesigned website to mark 60th anniversary
- Huons Group Chairman Yoon returns as Huons Global CEO after 3-year hiatus